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In cellular immunity, thymus-derived (T)lymphocytes recognize antigens in the
context of cell surface glycoproteins encoded byM:iC genes (1, 2) . In general, T
lymphocytes expressing theCD4 antigen on their surface recognize antigens in as-
sociation with class II MHC molecules, such as I-A or I-E in mice andHLA-DR
or-DQinhumans, whereasTlymphocytesbearingtheCD8molecule are restricted
by class I MHC molecules, such as H-2K, -D, -L in mice and HLA-A, -B, -C in
humans . For bothTcell subsets, antigens are usually not seen in their native form
but only as some denatured or degraded form of the protein actively processed by
APCs (3, 4) and physically associated with class I or II MHC molecules (5, 6).
Recently much information about the detailed interaction between MHC mole-
cules and antigenic peptides has been accumulated, especially for ligand pairs rec-
ognized by class IIMHC molecule-restrictedThelper cells (7, 8) . However, detailed
studies on which amino acid residues are involved in binding to class IMHC mole-
cules for CD8' CTL recognition remain limited and have been carried out only
in a few antigen systems (9-11) . In this article we have analyzed the interaction be-
tween the class I DdMHC molecle and a CTL peptide epitope composed ofa 15-
residueamino acid sequence (315-329 : RIQRGPGRAFVTIGK) that we have iden-
tified in the HIV-1-111B gp160 envelope glycoprotein (12) . We have examined the
structural requirements of both Dd and of the peptide antigen for this interaction .
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First, we found that presentation of the epitope required both the specific al and
a2 domains of the Dd molecule, based on studies using L cell transfectants expres-
sing various recombinant or truncated class I molecules (13). Such an analysis with
reciprocally shuffled class I MHC domains has not previously been performed for
a defined antigenic peptide.
Second, the fact that this epitope derives from a naturally highly variable segment
of the HIV-1 envelope, and is seen by human CTL (14) as well as murine CTL (12),
afforded us the opportunity not only to study a class I MHC molecule-peptide in-
teraction, but also to analyze the structural basis for the loss ofT cell crossreactivity
as the virus mutates. In particular, since the CTL specific for this site on the HIV1-
IIIB isolate do not crossreact with the HIV1-RF variant isolate (15), we could use
the natural HIV variant sequences to dissect the role of each amino acid in the pep-
tide. We synthesized a series of peptides that differ at each ofthesepositions individ-
ually to determine which substitutions affect the presentation of the peptide, and
found that, surprisingly, only 322(R) and 324(F) appear to be the critical amino
acids for Dd binding and presentation. In contrast, residue 325(V) appears to affect
TCR interaction. Thus, a limited number of residues are critical for both interac-
tions, and natural variation of the virus involves mutations in both the portion inter-
acting with the TCR and the portion interacting with the MHC molecule. These
latter results are also discussed in the context ofviral escape from immune effectors,
in view ofthe fact that this peptide is also an epitope for human HIV envelope-specific
CTL (14).
Materials and Methods
Recombinant Vaccinia Virus.
￿
vSC-25 (recombinant vaccinia virus expressing the HIV1-IIIB
gp160 envelope glycoprotein without other structuralor regulatory proteins of HIV) has been
described (16) and was used for immunizing the mice to induce envelope specific CTL.
PeptideSynthesis andPurification.
￿
Most ofthe peptides were prepared by the multiple simul-
taneous peptide method of solid-phase peptide synthesis, in polypropylene mesh "tea-bags"
as described (17). Peptides were desalted by reverse-phase chromatography on C18 Sep-Pak
columns (Waters Associates, Milford, MA), and analyzed by HPLC. Some peptides were
prepared by an automated peptide synthesizer (model 430A; Applied Biosystems, Inc., Foster
City, CA) and purified by HPLC. All of the peptides contained >90% of the desired product.
Exon-shuffled Transfectants.
￿
Mouse L cell clones stably transfected with H-2D1 and H-2L
d
genes (T4.8.3 and T1.1.1, respectively) have been previously described (18). TransfectantsT37.2.1
(expressing the Dd, Dd, and Ld derived sequences for the al, a2, and a3 domains, respec-
tively) (19), T37.1.3 (L'LdDd) (20), T9.10.3 (DdLdLd) (20), and DMT34.5 (LdDdDd) (21) have
been described in detail elsewhere. DMT26.5S1 expresses a cell surface protein lacking the
al domain, but containing all other H-213d sequences (McCluskey, J., and D. H. Margulies,
unpublished observations). All transfectant cell lines were examined by FAGS analysis with
an appropriate panel of anti-H-213d and anti-H-20 mAbs to confirm their expressed pheno-
type before the performance of the functional studies reported here.
CTL Generation.
￿
BALB/c mice (Jackson Laboratories, Bar Harbor, ME) were immunized
intravenously with 101 PFU of recombinant vaccinia virus. 3-14 wk later, immune spleen
cells (5 x 106/ml in 24-well culture plates in complete T cell medium (CTM)' a (1 :1 mix-
ture of RPMI 1640 and EHAA medium containing 10% FCS, 2 mM L-glutamine, 100 U/ml
penicillin, 100 p.g/ml streptomycin and 5 x 10-5 M 2-ME) were restimulated for 6 d in vitro
with either 2.5 x 106/ml of recombinant vaccinia virus-infected syngeneic spleen cells (1 h,
37°C, multiplicity of infection [MOI] of 10:1) or 2 x 105/ml of gp160 gene-transfected,
MHC-identical fibroblasts (12). A long-term CTL line was also generated by repetitive stim-
ulation of immune cells with mitomycin C-treated (100 jig/ml for 30 min at 37°C), gp160TAKAHASHI ET AL.
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gene-transfected H-2d fibroblasts and 10% rat Con A supernatant-containing medium (rat
T cell Monoclone; Collaborative Research, Inc., Bedford, MA).
Cloning ofCTL.
￿
CTL clones were derived from the bulk lines through limiting dilutions
onto mitomycin C-treated HIV-1-111B gp160 envelope gene transfected BALB/c 3T3 fibro-
blasts as stimulator cells in the presence of l0o7o rat Con A supernatant in U-bottomed 96-
well plates at 0.3 cells/well and four clones (RT1, RT2, RT3, RT4) were obtained. Although
the stimulator cells expressed whole gp160 envelope protein, all the clones were specific for
the same 315-329 region (Takahashi, H ., unpublished observations).
CTL Assay.
￿
Cytolytic activity of in vitro secondary CTL, CTL lines, or CTL clones was
measured as previously described (12) using a 6-h assay with various "Cr-labeled targets,
as indicated in the legends. For testing the peptide specificity of CTL, effectors and "Cr-
labeled targets were mixed with various concentrations of peptide at the beginning of the
assay (22) or effectors were cocultured with peptide-pulsed targets. The percent specific 5'Cr
release was calculated as 100 x [(experimental release - spontaneous release)/(maximum
release - spontaneous release)] . Maximum release was determined from supernatants of
cells that were lysed by addition of 5% Triton-X 100. Spontaneous release was determined
from target cells incubated without added effector cells.
Inhibitory Effect of Several Peptides on the Presentation of 18IIIB at the Target Cell Level.
￿
Class
I Dd molecule-expressing fibroblasts were preincubated with competitor peptides at 20 /AM
overnight in the presence of 100p.Ci/ml of "Cr, then without removal of the competitor and
5'Cr, incubated with IpM of the epitope peptide 18IIIB (315-329) at 37°C for 1 h. After
the incubation, target cells were washed three or four times before use in the cytotoxic assay.
Results
Presentation of the Epitope Depends on Both al and a2 Domains of the Dd Molecule.
￿
In
previous studies, we have found that residues 315-329 of the HIV-1 IIIB envelope
protein constitute an immunodominant site for recognition by CD8+ CTL of H-
2d mice, and that this site is seen only with the class I molecule Dd (12). Because
Ld, which is homologous to Dd , does not present this peptide (12), we could use
recombinant Dd and Ld molecules to determine which domains ofthe Dd molecule
were specifically required for presentation of the peptide. The series of transfectants
made in H-2k L cell fibroblasts and expressing recombinant gene products is shown
in Table I. We used peptide-pulsed "Cr-labeled cells as targets of cytolysis by
H-2Dd-restricted peptide 18IIIB-specific cytotoxic T cell lines and clones, to avoid
self-presentation ofpeptide by the H-2d T cells. Only T37.2.1 (a1a2 of Dd) was sen-
sitized with the peptide to the same extent as the positive control T4.8 .3 L cell trans-
fectant expressing a class I molecule with all Dd domains (Table I). Because
DMT26.5S1 and DMT34.5 were not sensitized with the peptide, al deletion or al
substitution with the corresponding Ld domain abrogated the recognition of the
peptide. Conversely T9.10.3, with only al from Dd, was not sensitized by the pep-
tide. This result showed that the Dd al domain alone was not sufficient. Therefore,
we conclude that both specific al and a2 domains of Dd are necessary and together
sufficient in the context of a complete mouse class I molecule to present the peptide
and allow recognition by specific CTL.
The Effects ofSingleAmino Acid Substitutions on CTL Recognition.
￿
The CTL specific
for the immunodominant site of the HIV1-IIIB gp160 envelope protein represented
by a 15-residue synthetic peptide (18IIIB) (315-329: RIQRGPGRAFVTIGK) did
not crossreactively kill H-2d targets infected with recombinant vaccinia virus ex-
pressing the envelope gene from the natural HIV1-RF variant (15) or targets pulsed
with a peptide corresponding to the homologous site in the HIV1-RF gp160 enve-2026
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TABLE I
Both the al and a2 Domains of the D° Molecule Are Necessary
and Sufficient for Presentation and Recognition of the 18IIIB Determinant
' Target cells were pulsed overnight with 1 pM of peptide 18IIIB and washed
four times to remove free peptide.
Target ratio = 5/1 .
S TM: transmembrane portion of the Dd molecule.
I Effectors are CTL-LINE and clone RT-1 (see Materials and Methods).
lope protein(18RF) (315-329: --HIGPGRVIYATGQ). Therefore, by examiningthe
roleofeach residueat which these variantsdiffer, wecouldboth identify the residues
involved ininteractionwith theMHCmolecule orTCR andalso examine the struc-
turalbasis forthe effect ofviralvariationonT cell reactivity. We synthesized aseries
ofpeptides with single amino acid substitutions at each position in which 18IIIB
and 18RF differ or with an alanine substitution at positions conserved in the two
HIV isolates (Table II)to determine which substitutions affect interaction with the
TCRs ofthe CTL-LINE and clones (RT1, RT2, RT3) that we have developed, or
TABLE II
Substituted Peptides Usedfor Mapping Peptide Binding/Recognition
" Indicates a deletion.
t The underlined amino acids are substitutions in the 18IIIB sequence.
Sequence position
No. 18IIIB
No. 18 RF
315
R
*
I
*
Q
T
R
K
G
G
P
P
G
G
R
R
A
V
F
I
V
Y
T
A
I
T
G
G
329
K
Q
No. 18-1 _*t I Q R G P G R A F V T I G K
No. 18-2 R _*1 Q R G P G R A F V T I G K
No. 18-3 R I _T R G P G R A F V T I G K
No. 18-4 R I Q _K G P G R A F V T I G K
No. 18-5 R I Q R A_ P G R A F V T I G K
No. 18-6 R I Q R G _A G R A F V T I G K
No.18-7 R I Q R G P _A R A F V T I G K
No. 18-8 R I Q R G P G A_ A F V T I G K
No. 18-9 R I Q R G P G R _V F V T I G K
No. 18-10 R I Q R G P G R A I V T I G K
No.18-11 R I Q R G P G R A F _Y T I G K
No. 18-12 R I Q R G P G R A F V A_ I G K
No. 18-13 R I Q R G P G R A F V T T_ G K
No. 18-14 R I Q R G P G R A F V T I _A K
No. 18-15 R I Q R G P G R A F V T I G Q.
L cell
transfectant
targets' al
Class I
a2
Dd molecules
0 TMS
Percent specific
lysist
LINE11 RT-Idl
T4.8.3 Dd Dd Dd Dd 25.9 25 .2
T1 .l.l Ld Ld Ld Ld 1 .9 1 .9
DMT26.5S1 - Dd Dd Dd 3.8 5 .2
T37 .2.1 Dd Dd Ld Ld 27.1 34.0
T37.1 .3 Ld Ld Dd Dd -4.9 -2.9
T9.10.3 Dd Ld Ld Ld -6.9 -7.5
DMT34.5 Ld Dd Dd Dd 3.5 1 .5with the Dd molecule. The results are summarized in Figs. 1 and 2. Although there
is some shift in the dose-response curves for most ofthe substituted peptides (18-3
to 18-13) compared withthe wild-typepeptide 18IIIB, thedataclearly demonstrated
that substitutions only at positions 322(R) (18-8), 324(F) (18-10), and 325(V) (18-11)
markedly affect CTL activity. In comparing the activities of clone RT1 and RT3,
substitutions of322(R) with Ala and of325(V) with Tyr were each less detrimental
for clone RT3 than clone RT1, but substitution of 324(F) with Ile abrogated the
CTL response completely forboth clones. The variable effect ofsubstitutions atpo-
sitions 322 and 325 for different clones (Fig. 2) was consistent with the partial loss
of activity for the CTL-LINE (Fig. 1), whereas the uniform effect ofsubstitution
at position 324 for the clones was consistent with complete loss of activity for the
line. Theseeffectscouldbe due to interference with peptidebinding toclass I MHC
molecules, or to interference with TCR recognition. To distinguish these mecha-
nisms, we measured competition for class I MHC molecule presentation.
Competition Analysis of the Substituted Peptides with Diminished Activity in the CTL Re-
sponse. Substitution of322(R) with Ala and 324(F) with Ile and 325(V) with Tyr
decreased or eliminated the ability ofthe peptide to sensitize target cells. To inves-
tigate whether the decreased activity is dueto diminished Dd binding or to changes
in the interaction with the TCR, we pulsed the Dd-expressing targets with high con-
centrations ofthe substituted peptides together with "Cr overnight and then added
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FIGURE 1.
￿
The effects ofsingle amino acid sub-
stitutions on recognition of variant epitopes by
a IIIB-specific CTL-LINE. Peptide 18IIIB-
specific CTL-LINE was added to "Cr-labeled
BALB/c 3T3 fibroblast target cells in the pres-
ence of indicated concentrations of substituted
peptides as shown in Table 11. E/T ratio was 5:1
in each case.
No. 18 No. 18-1 No. 18-2 No. 18-3
No. 18-4 W-18-5 No. 18-6 No. 18-7
No. 18-8 No. 18-9 No. 18-10 No. 18-11
No. 18-12 No, 18-13 No. 18-14 No. 18-152028
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FIGURE 2 .
￿
The effects ofsingle amino acid substitutions on peptide sensitization oftargets for
recognition by individual CTL clones . Clones RT 1, RT2, and RT3 specific for peptide 18IIIB
were tested for recognition of BALB/c 3T3 fibroblast targets in the presence 10 AM of the sub-
stituted peptides as shown in Table II . E/T ratio was 5 :1 in each case.
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-o-- No Inhibitory peptide
18-10 (324(F-4))
18-8 (322 (R-A))
FtcuRE 3 .
￿
Peptides substituted
at 322 and 324 fail to compete
with wild-type peptide 18IIIB
for presentation toCTL . Com-
petition method was as follows:
El--
￿
peptide19 (324-330)
￿
BALB/c 3T3 fibroblasts (H-2d)
were preincubated with compet-
itor peptidesat 20AM overnight
'~ -e- No peptide
￿
in the presence of 100 WCi/ml
of 5ICr, then without removal
r-~
￿
of the competitor and 51 -Cr, in
2 .5/1
￿
5/1
￿
10/1
￿
cubated with 1 AM of the epi-
E/T Ratio
￿
tope peptide 18IIIB (315-329)
at 37°C for 1 h . After the incu-
ClOne RT-1
￿
No Inhibitor peptide
￿
bation, target cells were washed
three to fourtimes before use in
the 6-h cytotoxic assay . Although
No . 18-8 (322 (R -"A))(" ) and
No. 18-10 (324 (F- I)) (/) did
not inhibit the presentation of
18IIIB, No. 18-11 (325 (V- Y))
--o-- peptide 19 (324-336)
￿
(A) did partially inhibit the pre-
-
￿
sentation . Peptide 19 (324-338)
EI) was used as a positive inhib-
iyor control . Standard errors of
the means oftriplicate cultures
T~
￿
were always <5% ofthe mean .
2 .5/ 1 5/1
￿
10/1
t 18-10(324(F-4))
18-8 (322 (R-A))
"A-- 18-11(325(V-Y))TAKAHASHI ET AL.
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1 pM 18IIIB for60 min. Afterthe incubation, cells were harvested andwashed care-
fully fourtimesto remove free peptides before beingused as targets. As Fig. 3 shows,
we could not detect any significant inhibitory activity ofpeptides substituted at ei-
ther322 or324 for the CTL-LINE or clone. As a control, we showthat the overlap-
ping peptide 19, residues 324-338, can inhibit under these conditions. As failure
to compete during pulsingsuggests failure to bind the MHC molecule, these results
suggest that positions 322(R) and 324(F) may both be involved in determining the
extent ofpeptide bindingto the Dd class I MHC molecule. In contrast, the peptide
with substitution of325(V), which strongly affected responseofonlyone ofthe CTL
clones, did partially inhibit presentation ofwild-type 18IIIB to this clone (Fig. 3,
bottom paneo. Since at high concentrations this peptide sensitizes targets for all of
the CTL clones, it is not possible to achieve complete inhibition. Since ability to
compete during pulsing oftargets with peptide, in the absence ofT cells, generally
indicates competition for MHC molecule bindingand therefore the ability to bind,
these data suggest that 325(V) affects interaction with the TCR. Also, successful
competition by overlapping peptide 19 (324-338) indicates that this peptide binds
to Dd even though it does not sensitize targets. The simplest explanation is that pep-
tide 19 shares enough of the Dd binding structure ofpeptide 18IIIB to bind. It is
formally possible that this peptide has a distinct Dd binding site inresidues 330-338,
which are not seen because ofahole in the T cell repertoire. However, the observed
scarcity ofpeptides presented by Dd in this molecule (12) and the rarity ofholes in
theTcellrepertoire (23)meanthat tworelativelyunlikelyevents would havetocoincide
for the latter interpretation to hold.
Discussion
Using a series ofoverlappingpeptides ofthe HIV1-IIIB gp160 envelope glycopro-
tein, we have previously identified an immunodominant site for CTL recognition
(12), basedon the methods ofTownsend et al. who showed that antigens recognized
by CTL can be mimicked by synthetic peptides (22). The immunodominant epi-
tope recognized by H-2d mice consists ofa 15-residue sequence (18IIIB: RIQRGP-
GRAFVTIGK). By use oftwo H-2k L cell fibroblast transfectants, we demonstrated
that recognition ofthe epitope 18IIIB is restricted by the class I Dd molecule, not
the Ld molecule. We took advantage ofthis well-defined system to determine struc-
tural requirements ofCTL activity forboth the class I molecules and the antigenic
peptide, and to explore the structural basis for the effect ofviral variation on T cell
reactivity.
It has already been reported that allospecific and influenza virus-specific CTL
are restricted to the cd and/or a2 domain ofclass I molecules (13, 24). It has also
been reported that the frequencyofmurine CTL precursors (CTLp) that recognize
the humanhistocompatibility antigen HLA-A2 and HLA-B7 is controlled bystruc-
tures within cd and a2 domains ofthe class I molecules (25). Although the three-
dimensional structure ofthe class I molecule (26, 27) makes it likely that both al
and a2 domainsmayplay some role in peptidebinding, previous experiments indi-
cate that the cd domain ofDd is sufficient for allorecognition by anti-H-2Dd CTL
when associated with the a2 and 0 domains ofLd (21). To determine whether the
response to the immunodominant epitope ofthe HIV1-IIIB envelope protein also
depends on both the al and a2 domains ofthe Dd class I molecules, we used sev-2030
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era] L cell (H-2k) transfectants with different exon shuffles between Dd and Ld (Table
I). Theresults revealed that the 18IIIB peptide requires both theal anda2 domains
ofthe Dd molecule for effective presentation. These two domains of Dd alone are
sufficient, in the context ofacomplete murine class I molecule, for presentation of
the immunodominant site. Furthermore, neither the al nor the a2 domain ofDd,
when the other derives from Ld, is alone sufficient for presentation of the peptide.
We conclude that both the al and the 0 domains ofthe Dd molecule are neces-
sary and together sufficient in an intact class I MHC molecule for presentation of
the epitope. Previous studies ofclass I molecules with exon shuffles (19-21, 24, 25)
have largelydealt withallorecognition, andin particular, have not dealtwithpresen-
tation ofadefinedpeptide. Arecent study by McMichaeletal. (28) usingsite-directed
mutants ofthe humanclass I molecule HLA-A2.1 also suggests that residues ofboth
the al and a2 domains play arolein bindingofapeptide fromthe influenzamatrix
protein. Very recently, Martinon et al. (29), using H-2Kd/Dd recombinant mole-
cules, have demonstrated the importance of residues 152, 155, and 156 in the a2
domain ofKd in the presentation of an HLA peptide. However, without reciprocal
recombinants, this study was unable to address the role of the a1 domain of Kd.
Acomparison ofthe residues that differ between H-2D' and H-2Ld in the al and
a2 domains (30) andconsiderationoftheirlikely structural relationship based upon
thethree-dimensional structureofthehomologous humanHLA-A2.1 molecule (26,
27) and ofa model of the murine H-2K6 molecule (31) offer some understanding
of the residues critical for binding of the HIV peptide 18IIIB to Dd or to the H-
2Dd-restricted CTL. Ofthe 18 residues that differ between H-2Dd and H-2L' in
the al domain, and the 8 residues that differ in the 0 domain, only 10 are likely
to be either facing the antigen binding cleft or directly accessible to the TCR and
are nonconservative. Thus, positions 9, 31, 63, 65, 66, 73, 77, 114, 155, and 156 are
likely to play an important role in either the interaction of peptide 18 with the H-
2Dd molecule, or ofthe peptide/MHC complexwith the TCR. Further experiments
usingan invitro mutagenesis approach should clarifythe roleofeachofthesepositions.
Becausethe IIIB CTLdeterminantlies ina region ofgp160 that ishighly variable
among the different HIV-1 isolates (32), we could use naturally occurring substitu-
tions in the gp160 sequence to define the roles ofindividual peptide residues in im-
mune recognition. The CTL line specific for peptide 18IIIB from the HIV1-IIIB
isolate did not crossreactively kill targets infected with recombinant vaccinia virus
expressing the envelope gene fromthe RF isolate ortargetspulsed with thehomolo-
gous peptideofthe RF gp160 envelopeprotein(18RF). As shown inTable II, aseries
ofpeptides that differ by each ofthese substitutionsindividuallywasmade to deter-
minewhich substitutions were responsible for the lack ofresponse ofthe anti-HIV
1-IIIB CTL to the HIV1-RF peptide. The results clearly showed that substitutions
of322(R) by Ala and 324(F) by Ile markedly reduced the CTL recognition ofthe
peptide, and the latter substitution appeared to be more critical (Figs. 1 and 2).
Moreover, neitherofthesetwosubstitutedpeptides inhibitedthebindingoftheoriginal
peptide 18IIIB (Fig. 3). Therefore, we may conclude that, among the 15-residues
ofthe peptide, 322(R) and 324(F) may be critical in controlling binding to the Dd
class I molecule (agretopic amino acids). The data also suggest that residue 325(V)
may be involved in TCR interaction. Furthermore, in spite of not containing the
agretopic residue 322(R), the peptide 324-338 seems to be able to bind to the DdTAKAHASHI ET AL.
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molecule (Fig. 3). Taking everything together, the critical residues for binding to
Dd and also to the TCR appear to be between residues 324 and 329. While 322(R)
is not contained in this region, it appears to also contribute to the binding to Dd,
orat least its substitution with Ala interferes either directly orvia a conformational
effect. Interestingly, our results are compatible with the recent results of Gotch et
al. (10) on presentation ofa peptide ofinfluenza matrix protein by HLA-A2. These
investigators found that the most effective substitutions for abrogating the ability
to sensitize the targets were substitutions at an agretopic residue (residue 61), i.e.,
onethat was found tobe part ofthe sitebindingtothe class I MHC molecule. How-
ever, the observation thatonlyone ortwo residues are critical forclass I presentation
is somewhat surprising inview ofthefindingfor class II-restricted presentation that
in some experiments has been shown to be affected by substitutions at each ofsev-
eral positions (33, 34), and in view offraction ofthe peptide structure that could
be enclosed within the MHC groove (26, 27).
The peptide 18IIIB has a sequence with the right periodicity ofhydrophobicity
to form an amphipathic ac-helix. Although the GPG sequence intheimmunodominant
epitope will probably induce abend in the predicted helix, the region startingfrom
GPGthroughthe COOH terminuscan form three amphipathic ce-helicalturns. The
data suggest that this is the critical region for class I MHC molecule binding and,
therefore, for CTL recognition, consistent with the helical amphipathicity hypoth-
esis (35-37).
Because thissameHIV peptide isalso recognized byhumanCTL(14), these results
may have clinical implications for HIV infection. Comparing the sequence ofthis
immunodominant CTL determinant in the HIV1-IIIB sequence with the corre-
sponding region inthe sequence ofthe HIV1-RF isolate, it is ofinterest thatchanges
appear to take place in both the residues that are required for class I MHC binding
(agretopic residues) and residues that determine T cell specificity or TCR interac-
tion (epitopic residues). Although a mutant virus may not have a selective advan-
tage against CTL in thecell inwhich it arises, in the midst ofotherwild-typevirions,
if it buds before that cell is lysed and infects another cell at a multiplicity of one,
it would have an advantage in escaping CTL. Changes in epitopic residues might
affect susceptibility ofthe virus to immune defense mechanisms ifthe T cell reper-
toire varies among individuals, although the repertoires are thought to be broad
enough that this may be relatively rare. Nevertheless, the rarity of class I MHC-
restricted epitopes in several proteins (12, 38, 39) suggests that perhaps the reper-
toire ofdeterminants recognized in association with class I MHC molecules is less
broad than expected. Changes in agretopic residues would be expected to have a
more profound effect in that they would determine which individuals, ofdifferent
HLAtypes, could raise anyCTL response at all againstthisimmunodominant epi-
tope in associationwith their class I molecules. Furthermore, it hasbeenshown that
the HIV virus can mutate within the course ofdisease in a single individual (40,
41). Ifmutationsoccur only in epitopicresidues, existingCTLmaybemadeineffec-
tual, but newCTL could be elicited that see the new mutant epitope with the same
MHC molecule. On the other hand, if mutations occur in agretopic residues, it is
possible that the mutant determinant may not be able to be presented by any of
the class I MHC molecules of that individual. Thus, if only a single CTL deter-
minant is available on that protein ofthe virus, as appears to be the case here for2032
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the HIV envelope as seen by H-2d mice, the individual would become immunolog-
ically blind to thatprotein o£the mutant virus with respect toclass I-restricted effector
cells. We might speculate, then, that ifclassI-restricted CTL are an important host
mechanism keeping HIV in check during the usually longlatency period ofthe in-
fection (42), such a mutational event in which the mutant virus becomes at least
partially immunologically invisible to the host may allow the virus to escape im-
mune control, replicate rapidly, and cause AIDS. Ofcourse, CTL specific forother
proteins ofthe virus might prevent this, but ifonly afewproteins are critical targets
for CTL and if each ofthese has only one or two immunodominant epitopes, then
mutation ofjust a few ofthese epitopes may be enough to tip the balance and allow
virus to escape control in that individual. For these reasons, it would be valuable
to compare sequences of such epitopes in serial isolates ofvirus from the same pa-
tient as the disease progresses.
Summary
In H-2d mice, the immunodominant determinant ofthe HIV1-IIIB gp160 enve-
lope glycoprotein recognized by CD8+ CTL is represented by a 15-residue synthetic
peptide (315-329: RIQRGPGRAFVTIGK). This peptideisseen in association with
the Dd class I MHC molecule expressed on H-2k L cell fibroblast targets. We ex-
plored the structural requirements for CTL recognition ofthis peptide at the levels
ofboth the peptide molecule andthe classI MHC molecule. Usingseveral transfec-
tants expressing recombinant Dd/Ld molecules, we found that presentation o£this
epitope required both the al and u2 domains of the Dd molecule, in contrast to
certain instances ofallorecognition forwhich al ofDd was sufficient in association
with 0 of Ld.
Because this peptide derives from a hypervariable segment ofthe HIV envelope,
substituted peptides couldbe used todefine notonly the structures affectinginterac-
tion of peptide with class I MHC molecule and with the TCR, but also the struc-
tural basis for the effect ofnaturally occurring viral variation on CTL recognition.
The CTL-LINE specific for this HIV1-IIIB-derived sequence could not recognize
the HIV1-RFvariant-derived sequence from exactlythe same site(315-329: --HIG-
PGRVIYATGQ). Peptides with single amino acid substitutions from the HIV1-IIIB
sequence toward the HIV1-RF sequence were made totestthe effect ofeach residue
onthe ability to sensitizetargets. The resultsclearly showed that onlythree residues
significantly affected recognition, and only one, 324(F), was obligatory. Moreover,
both 322(R) and 324(F) substituted peptides failed to inhibit the bindingofthe wild
type peptide to the MHC molecule. Therefore, the amino-acids 322(R) and 324(F)
seemtobe involved in regulating peptide interaction with the Dd class I MHC mol-
ecule. In contrast, 325(V) appeared to affect interaction with the TCR. We suggest
that sequence variations among known HIV-1 isolates that affect peptide binding
to MHC such as those described here, ifoccurring during the course of infection
of an individual, could result in failure ofthe MHC molecules of that individual
to present the peptide. If the number of dominant HIV CTL epitopes is indeed
very limited, such a blind spot could allow the virus to escape immune control,
proliferate rapidly, and cause AIDS.We thank Dr. J. McCluskey for providing the DMT 26.551 transfectant, and Dr. Thomas
A. Waldmann for critical reading of the manuscript.
Receivedfor publication 3 August 1989.
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